Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can one number judge colonoscopy quality for every patient?

NCT ID NCT05125939

Diagnosis Sponsor: Evergreen General Hospital, Taiwan Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 11, 2026 · Last updated Sep 11, 2026

Summary

Doctors often judge colonoscopy quality by how many screening patients have adenomas found, but that measure leaves out people who get colonoscopies for surveillance or symptoms. This study at multiple hospitals in Taiwan compares the screening-only adenoma detection rate with a broader rate that includes screening, surveillance, and diagnostic colonoscopies. Researchers enroll about 2,700 adults aged 50 and older without high-risk inherited conditions or inflammatory bowel disease. The goal is to see whether the broader measure is a reliable substitute for the screening-only one.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If the broader measure proves reliable, hospitals could track colonoscopy quality with one number instead of separating screening from other reasons, which may make quality reporting simpler and more consistent.
What could go wrong
This is an observational comparison, not a test of a treatment, so it cannot improve detection by itself. The findings may not hold in centers with different patient mixes or practices.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

2,707 people

The number who actually took part.

Started

Nov 2021

Finished

Aug 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

All patients aged ≥50 years undergoing screening, surveillance, diagnostic, and FIT+ colonoscopy are eligible for enrollment in this study.

Ages

50 to 80 years

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * consecutive patients aged ≥50 years undergoing colonoscopy are eligible for enrollment. Exclusion Criteria: * high risk family history of colorectal cancer (CRC) e.g., familial adenomatous polyposis, hereditary non-polyposis CRC syndrome, multiple first degree relatives with CRC, or a single first degree relative with CRC at \<60 years * serrated polyposis syndrome * inflammatory bowel disease * colonoscopy to remove a large neoplastic polyps * obstructive lesions of the colon * gastrointestinal bleeding * current participation in other studies * hospitalized patients * mental retardation * pregnancy * refusal to provide a written informed consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Adenoma detection rate are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Adenoma detection rate Colonoscopy

Contacts and locations

Locations

  • E-Da Dachang Hospital

    Kaohsiung City, 80784, Taiwan

  • E-Da Hospital

    Kaohsiung City, 82445, Taiwan

  • Evergreen General Hospital

    Taoyuan, 320, Taiwan

  • Keelung Chang Gung Memorial Hospital

    Keelung, 204, Taiwan

  • Linkou Chang Gung Memorial Hospital

    Taoyuan, 333, Taiwan

  • Sepulveda Ambulatory Care Center, VAGLAHS

    North Hills, California, 91343, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.